Gain Therapeutics (GANX) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Gain Therapeutics (GANX) over the past year, gaining 18.3% versus a loss of 62.4%. Over five years, RNXT leads with a -85.3% price change compared with -87.3% for GANX. RenovoRx is the larger company by market cap ($45.5 million vs $44.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | RNXT |
|---|---|---|
| Share price | $0.9994 | $0.942 |
| Market cap | $44.50M | $45.45M |
| 1-day change | -4.82% | -10.29% |
| YTD return | -68.96% | +12.14% |
| 1-year return | -62.43% | +18.34% |
| 5-year return | -87.27% | -85.26% |
| EPS (TTM) | $-0.42 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.12M |
| Revenue growth (YoY) | — | +2511.63% |
| Net income (latest FY) | $-20.16M | $-11.17M |
| Gross margin | — | 70.88% |
| Operating margin | — | -1113.98% |
| Net margin | — | -994.48% |
| 52-week high | $4.34 | $2.59 |
| 52-week low | $0.94 | $0.77 |
| Distance from 52-week high | -76.97% | -63.63% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +620.43% | +656.90% |
| Average volume | 550.22K | 815.75K |
| Shares outstanding | 44.53M | 48.25M |
| Employees | 20 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed GANX by 80.8 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
GANX vs RNXT FAQ
Which is bigger, Gain Therapeutics or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.50M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or RNXT?
RNXT returned +18.34% over the past 12 months, compared with -62.43% for GANX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.